Troy– Author –
-
Otsuka’s ADHD Therapy Poised for FDA Approval Following Successful Phase 3b Clinical Trial
Fierce Biotech USA Overview Otsuka Pharmaceutical announced positive outcomes from its Phase 3b clinical trial for an Attention-Deficit/Hyperactivity Disorder (ADHD) treatment, marking a crucial step ahead of its U.S. Food and Drug Admin... -
Elixirgen Therapeutics and Nippon Shinyaku Forge Alliance for Next-Gen DMD Therapy EXG-7001
GlobeNewswire Japan Overview Elixirgen Therapeutics and Nippon Shinyaku have signed an option agreement for the development and commercialization of EXG-7001, a promising therapeutic candidate for Duchenne Muscular Dystrophy (DMD). This ... -
Bayer and Iambic Therapeutics Partner to Drive Small Molecule Drug Discovery with AI Platform
BioSpace USA Overview Bayer has announced a strategic collaboration with Iambic Therapeutics, leveraging Iambic's advanced AI platforms, Enchant and NeuralPLexer, for small molecule drug discovery. This partnership aims to significantly ... -
Biotech CEOs Anticipate Funding Rebound by Late 2026, Pin Hopes on FDA for Streamlined Drug Development
Endpoints News USA Overview A recent Endpoints 100 survey reveals 62% of biotech CEOs anticipate a significant improvement in the funding environment by late 2026, driven by a recovering IPO market and increased M&A activity. These l... -
Antares and Novartis Forge $1.9B Deal to Tackle ‘Undruggable’ Cancer Targets with Small Molecules
Business Wire USA Overview Antares Therapeutics and Novartis have announced a strategic collaboration to discover, develop, and commercialize first-in-class small molecule therapies for previously 'undruggable' cancer targets. The agreem... -
Biogen Pivots Post-Apellis Acquisition: Halts Most R&D, Concentrates on Commercial Assets
Endpoints News USA Overview Biogen has confirmed it will suspend or terminate "most" of Apellis Pharmaceuticals' research programs and lay off some employees following its $5.6 billion acquisition. This strategic pivot is part of integra... -
RQ Bio Secures $115M to Fast-Track Long-Acting Antibody RQB01, Revolutionizing Flu Prevention for Vulnerable Patients
GlobeNewswire UK Overview RQ Bio has successfully closed a $115 million (approximately £85.5 million) Series A funding round, led by Frazier Life Sciences, to accelerate the clinical development of RQB01. This long-acting antibody progra... -
MAIA Biotechnology Completes Global Enrollment for Phase 2 Ateganosine Trial in Refractory NSCLC
GlobeNewswire USA Overview MAIA Biotechnology has completed global enrollment for Part C of its Phase 2 THIO-101 expanded trial, evaluating ateganosine for third-line advanced non-small cell lung cancer (NSCLC). Ateganosine, an investiga... -
BMS Reveals Promising Clinical Data for Next-Gen Blood Cancer Therapy Mezigdomide
BioPharma Dive USA Overview Bristol Myers Squibb (BMS) unveiled promising new clinical data for mezigdomide, its next-generation blood cancer therapy. This drug is one of two key protein degradation inducers BMS expects to succeed its mu... -
Novartis’ Acquired RNA Therapeutic del-brax Achieves Phase 1/2 Success for Muscle-Wasting Diseases
BioPharma Dive USA Overview Novartis' RNA therapeutic del-brax, acquired through its $12 billion purchase of Avidity Pharmaceuticals, successfully completed a Phase 1/2 clinical trial for muscle-wasting diseases, achieving its primary en...
